Magnetic Resonance Imaging of Vascular Function

Sponsor
Sunnybrook Health Sciences Centre (Other)
Overall Status
Unknown status
CT.gov ID
NCT02206919
Collaborator
Unity Health Toronto (Other)
60
1

Study Details

Study Description

Brief Summary

A major function of blood vessels is to control blood flow by dilating or constricting depending on the demand. Vascular dysfunction is a state in which blood vessels fail to carry out its normal roles such as regulating blood flow. Diabetes is a risk factor for vascular dysfunction. Dysfunction may involve the smaller and/or larger blood vessels. Failure in the ability of large (conduit) blood vessels to control blood flow may be an early feature of atherosclerosis, a leading cause of stroke and heart attack. Measures of blood vessel dilation give an indication of the health of the vessel. Ultrasound and MRI can assess vascular function by measuring changes in blood vessel dilation. Diabetes may also affect tiny vessels in the kidney. These vessels become porous allowing albumin (a protein in the blood) to leak into the urine. The investigators can easily measure the presence of albumin in the urine.

This study aims to explore if MRI can demonstrate an association between vascular health in tiny and larger (conduit) blood vessels, by testing for an association between blood flow regulatory capacity of large vessels and presence of albumin in the urine.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Magnetic Resonance Imaging of Vascular Function
    Study Start Date :
    Jun 1, 2014
    Anticipated Primary Completion Date :
    Nov 1, 2015

    Outcome Measures

    Primary Outcome Measures

    1. Popliteal FMD MRI technique correlates with albuminuria in those with early diabetic disease [One year]

      If this MRI technique is sensitive enough to demonstrate an association between flow mediated dilatation (FMD) of the popliteal artery and albuminuria, this will make a case for the use of the MRI technique in measuring effects of various interventions on vascular function.

    Secondary Outcome Measures

    1. Blood measures related to cardiovascular disease and renal function [One year]

    2. Dietary risk factors related to chronic disease [One year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Men and women with type 2 diabetes who:

    • are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks

    • have diabetes diagnosed >6 months

    • have maintained stable weight for 2 months (within 3%)

    • have a valid Ontario Health Insurance Plan (OHIP) card and a family physician

    • if prescribed lipid medication, have taken a stable dose for at least 2 weeks

    • if prescribed blood pressure medication, have taken a stable dose for at least 1 week

    • can keep written food records

    • carotid intima-media thickness (cIMT) < 1.2 mm and ankle brachial index (ABI) of

    0.9.

    Exclusion Criteria:
    • Individuals who

    • take insulin

    • take steroids

    • have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS)

    • have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months

    • take warfarin (Coumadin)

    • have had major surgery in the past 6 months

    • have a major debilitating disorder

    • have clinically significant liver disease ( liver transaminase levels > 130 U/L), excluding Nonalcoholic fatty liver (NAFL) disease or NASH

    • have hepatitis B or C

    • have renal failure (high creatinine > 150 mmol/L)

    • have serum triglycerides ≥ 6.0 mmol/L

    • have a history of cancer, except non-melanoma skin cancer (basal cell, squamous cell)

    • have food allergies to study food components

    • have acute or chronic infections (bacterial or viral)

    • have chronic inflammatory diseases (e.g. rheumatoid arthritis, lupus; ulcerative colitis)

    • have other conditions which in the opinion of any of the investigators would make them unsuitable for the study

    • Any condition or circumstance which would prevent an individual from having an MRI (e.g. individuals with prostheses or metal implants, or those who are excessively claustrophobic)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St Michael's Hospital Toronto Ontario Canada M5B 1W8

    Sponsors and Collaborators

    • Sunnybrook Health Sciences Centre
    • Unity Health Toronto

    Investigators

    • Principal Investigator: Alan Moody, DR, Sunnybrook Health Sciences Center
    • Principal Investigator: David Jenkins, DR, Unity Health Toronto

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Alan Moody, Staff physician, Sunnybrook Health Sciences Centre
    ClinicalTrials.gov Identifier:
    NCT02206919
    Other Study ID Numbers:
    • 066-2013
    First Posted:
    Aug 1, 2014
    Last Update Posted:
    Aug 1, 2014
    Last Verified:
    Jul 1, 2014

    Study Results

    No Results Posted as of Aug 1, 2014